Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma

BACKGROUND: Responses to bevacizumab in glioblastoma (GBM) are not durable. Plasma levels of basic fibroblast growth factor (bFGF) increase at the time of tumor progression. By targeting vascular endothelial growth factor receptor (VEGFR), platelet‐derived growth factor receptor, Src, and FGF recept...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Med
Hlavní autoři: Lee, Eudocia Q., Muzikansky, Alona, Duda, Dan G., Gaffey, Sarah, Dietrich, Jorg, Nayak, Lakshmi, Chukwueke, Ugonma N., Beroukhim, Rameen, Doherty, Lisa, Laub, Caroline Kane, LaFrankie, Debra, Fontana, Brittney, Stefanik, Jennifer, Ruland, Sandra, Caruso, Victoria, Bruno, Jennifer, Ligon, Keith, Reardon, David A., Wen, Patrick Y.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Clinical Cancer Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6792497/
https://ncbi.nlm.nih.gov/pubmed/31444999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2505
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky